Journal de la science et de la recherche sur le cancer
Libre accès

Abstrait

lncRNAs: As novel biomarkers in diagnosis, prognosis and therapy of nonsmall cell lung cancer (NSCLC)

Xianfeng Ding

Non-small cell lung cancer (NSCLC) is a subtype of lung cancer that behaves similarly to squamous cell carcinoma
and adenocarcinoma. Non-small cell lung cancer (NSCLC) is the most common histopathological type, accounting
for about 85% of all lung cancers, and is usually diagnosed at advanced stages. Symptoms include persistent cough,
shortness of breath, weight loss, or hemoptysis. Surgery combined with chemotherapy improved the long-term survival of patients with NSCLC, but the emergence of drug resistance made chemotherapy less effective. Many lncRNAs
are functionally associated with human diseases, especially cancer. Long non-coding RNAs (lncRNAs)- dysregulation
has been reported to be involved in breast cancer, colorectal cancer, liver cancer, lung cancer, and leukemia. Commonly, lncRNAs dysregulation exerts impacts on cellular functions such as cell proliferation, resistance to apoptosis,
induction of angiogenesis, the advancement of metastasis, and evasion of tumor suppressors. This review provides
insight into (lncRNAs) covering a wide range of topics, such as biogenesis, effects on gene expression and regulation,
and potential use for biomarkers in the diagnosis, prognosis, and treatment of non-small cell lung cancer (NSCLC).